Epoxide hydrolases: their roles and interactions with lipid metabolism - PubMed (original) (raw)
Review
Epoxide hydrolases: their roles and interactions with lipid metabolism
John W Newman et al. Prog Lipid Res. 2005 Jan.
Abstract
The epoxide hydrolases (EHs) are enzymes present in all living organisms, which transform epoxide containing lipids by the addition of water. In plants and animals, many of these lipid substrates have potent biologically activities, such as host defenses, control of development, regulation of inflammation and blood pressure. Thus the EHs have important and diverse biological roles with profound effects on the physiological state of the host organisms. Currently, seven distinct epoxide hydrolase sub-types are recognized in higher organisms. These include the plant soluble EHs, the mammalian soluble epoxide hydrolase, the hepoxilin hydrolase, leukotriene A4 hydrolase, the microsomal epoxide hydrolase, and the insect juvenile hormone epoxide hydrolase. While our understanding of these enzymes has progressed at different rates, here we discuss the current state of knowledge for each of these enzymes, along with a distillation of our current understanding of their endogenous roles. By reviewing the entire enzyme class together, both commonalities and discrepancies in our understanding are highlighted and important directions for future research pertaining to these enzymes are indicated.
Similar articles
- Role of epoxide hydrolases in lipid metabolism.
Morisseau C. Morisseau C. Biochimie. 2013 Jan;95(1):91-5. doi: 10.1016/j.biochi.2012.06.011. Epub 2012 Jun 18. Biochimie. 2013. PMID: 22722082 Free PMC article. Review. - Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical.
Morisseau C, Hammock BD. Morisseau C, et al. Pest Manag Sci. 2008 Jun;64(6):594-609. doi: 10.1002/ps.1583. Pest Manag Sci. 2008. PMID: 18383502 Review. - Epoxide hydrolases: biochemistry and molecular biology.
Fretland AJ, Omiecinski CJ. Fretland AJ, et al. Chem Biol Interact. 2000 Dec 1;129(1-2):41-59. doi: 10.1016/s0009-2797(00)00197-6. Chem Biol Interact. 2000. PMID: 11154734 Review. - A Clinical Perspective of Soluble Epoxide Hydrolase Inhibitors in Metabolic and Related Cardiovascular Diseases.
Verma K, Jain S, Paliwal S, Paliwal S, Sharma S. Verma K, et al. Curr Mol Pharmacol. 2022;15(5):763-778. doi: 10.2174/1874467214666210920104352. Curr Mol Pharmacol. 2022. PMID: 34544352 Review. - Mammalian epoxide hydrolases in xenobiotic metabolism and signalling.
Decker M, Arand M, Cronin A. Decker M, et al. Arch Toxicol. 2009 Apr;83(4):297-318. doi: 10.1007/s00204-009-0416-0. Epub 2009 Apr 2. Arch Toxicol. 2009. PMID: 19340413 Review.
Cited by
- Microsomal epoxide hydrolase 1 (EPHX1): Gene, structure, function, and role in human disease.
Václavíková R, Hughes DJ, Souček P. Václavíková R, et al. Gene. 2015 Oct 15;571(1):1-8. doi: 10.1016/j.gene.2015.07.071. Epub 2015 Jul 26. Gene. 2015. PMID: 26216302 Free PMC article. Review. - Autoantibody response to microsomal epoxide hydrolase in hepatitis C and A.
Akatsuka T, Kobayashi N, Ishikawa T, Saito T, Shindo M, Yamauchi M, Kurokohchi K, Miyazawa H, Duan H, Matsunaga T, Komoda T, Morisseau C, Hammock BD. Akatsuka T, et al. J Autoimmun. 2007 Feb;28(1):7-18. doi: 10.1016/j.jaut.2006.12.005. Epub 2007 Feb 12. J Autoimmun. 2007. PMID: 17296285 Free PMC article. - Inhibition of the soluble epoxide hydrolase by tyrosine nitration.
Barbosa-Sicard E, Frömel T, Keserü B, Brandes RP, Morisseau C, Hammock BD, Braun T, Krüger M, Fleming I. Barbosa-Sicard E, et al. J Biol Chem. 2009 Oct 9;284(41):28156-28163. doi: 10.1074/jbc.M109.054759. Epub 2009 Aug 24. J Biol Chem. 2009. PMID: 19704161 Free PMC article. - Soluble epoxide hydrolase inhibitors and heart failure.
Qiu H, Li N, Liu JY, Harris TR, Hammock BD, Chiamvimonvat N. Qiu H, et al. Cardiovasc Ther. 2011 Apr;29(2):99-111. doi: 10.1111/j.1755-5922.2010.00150.x. Cardiovasc Ther. 2011. PMID: 20433684 Free PMC article. Review. - Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys.
Ulu A, Appt S, Morisseau C, Hwang SH, Jones PD, Rose TE, Dong H, Lango J, Yang J, Tsai HJ, Miyabe C, Fortenbach C, Adams MR, Hammock BD. Ulu A, et al. Br J Pharmacol. 2012 Mar;165(5):1401-12. doi: 10.1111/j.1476-5381.2011.01641.x. Br J Pharmacol. 2012. PMID: 21880036 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- 1 P01 ES11269/ES/NIEHS NIH HHS/United States
- P30 DK35747/DK/NIDDK NIH HHS/United States
- P30 ES05707/ES/NIEHS NIH HHS/United States
- P42 ES04699/ES/NIEHS NIH HHS/United States
- R01 HL699-06A1/HL/NHLBI NIH HHS/United States
- R37 ES02710/ES/NIEHS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources